Table 2. Clinical outcomes.
Data expressed as n (%) unless otherwise specified.
TXA: tranexamic acid; FFP: fresh frozen plasma; ED: emergency department; ICU: intensive care unit; LOS: length of stay; SD: standard deviation; IQR: interquartile range.
| Total (n = 16) | |
| TXA adverse effects | |
| Hypotension | 0 (0) |
| Anaphylaxis or hypersensitivity reaction | 0 (0) |
| Thrombosis within 28 days | 0 (0) |
| FFP adverse effects | |
| Transfusion-associated circulatory overload | 0 (0) |
| Transfusion-related acute lung injury | 0 (0) |
| Worsening angioedema | 0 (0) |
| Resolution of symptoms | |
| None | 2 (13) |
| Partial | 12 (74) |
| Complete | 2 (13) |
| Time from TXA administration to resolution (minutes), mean (SD) | 100 (26) |
| Repeat TXA dose required | 1 (6) |
| Repeat FFP dose required | 0 (0) |
| ED disposition | |
| Home | 6 (38) |
| Medical floor | 7 (44) |
| ICU | 3 (18) |
| ED LOS (hours), mean (SD) | 3.5 (1.9) |
| Mechanical ventilation required | 2 (13) |
| Duration of mechanical ventilation (days), mean (SD) | 2.5 (1.4) |
| Hospital LOS (days), median (IQR) | 1.5 (0.8 - 2.8) |
| ICU transfer required | 3 (18) |
| ICU LOS (days), median (IQR) | 1.9 (1.5 - 6.2) |
| Discharge disposition | |
| Alive | 16 (100) |
| Deceased | 0 (0) |
| Palliative | 0 (0) |
| ED visit for recurrent attack within 90 days | 1 (6) |